recombinant human growth hormone
GPTKB entity
Statements (120)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:protein peptide pharmacological class |
| gptkbp:abbreviation |
rhGH
|
| gptkbp:administeredBy |
injection
oral intravenous subcutaneous injection |
| gptkbp:alternativeName |
growth_hormone
growth_hormone_secretagogue recombinant_human_erythropoietin |
| gptkbp:approvedBy |
gptkb:FDA
1989 |
| gptkbp:ATCCode |
B03XA01
|
| gptkbp:bannedIn |
gptkb:World_Anti-Doping_Agency
|
| gptkbp:brand |
gptkb:Genotropin
gptkb:Humatrope gptkb:Norditropin gptkb:Nutropin gptkb:Omnitrope gptkb:Saizen gptkb:Zomacton |
| gptkbp:category |
peptide
glycoprotein hormone non-peptide hematopoietic growth factor |
| gptkbp:contraindication |
gptkb:proliferative_diabetic_retinopathy
uncontrolled hypertension active malignancy acute critical illness hypersensitivity to albumin |
| gptkbp:discoveredBy |
gptkb:Amgen
1980s |
| gptkbp:discoveredIn |
1980s
|
| gptkbp:effect |
increases plasma growth hormone levels
|
| gptkbp:example |
ghrelin
GHRP-2 GHRP-6 hexarelin ipamorelin macimorelin |
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:function |
stimulates secretion of growth hormone
|
| gptkbp:gene |
gptkb:GH1
gptkb:EPO |
| gptkbp:glycosylation |
highly glycosylated
|
| gptkbp:halfLife |
4-13 hours
|
| gptkbp:hasMolecularFormula |
C990H1528N262O300S7
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:darbepoetin_alfa
gptkb:epoetin_alfa |
| gptkbp:mechanismOfAction |
binds to growth hormone secretagogue receptor (GHSR)
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
~22 kDa
30-40 kDa |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:producedBy |
gptkb:E._coli
gptkb:Chinese_hamster_ovary_cells recombinant DNA technology mammalian cells baby hamster kidney cells genetically engineered cells |
| gptkbp:promotion |
erythropoiesis
red blood cell production |
| gptkbp:regulates |
prescription
erythropoietin receptor |
| gptkbp:relatedTo |
gptkb:pituitary_gland
gptkb:growth_hormone-releasing_hormone |
| gptkbp:replacedBy |
pituitary-derived human growth hormone
|
| gptkbp:riskFactor |
increased mortality in some populations
tumor progression in cancer patients |
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
gptkb:carpal_tunnel_syndrome
edema hypertension joint pain muscle pain thromboembolic events pure red cell aplasia increased risk of diabetes |
| gptkbp:SIM |
endogenous erythropoietin
|
| gptkbp:structure |
165 amino acids
191 amino acids |
| gptkbp:target |
bone marrow
growth hormone-releasing receptor |
| gptkbp:usedFor |
gptkb:Noonan_syndrome
gptkb:Prader-Willi_syndrome gptkb:Turner_syndrome chronic kidney disease adults with growth hormone deficiency muscle wasting short bowel syndrome treatment of anemia chemotherapy-induced anemia growth hormone deficiency HIV-associated wasting children born small for gestational age idiopathic short stature small for gestational age children with SHOX deficiency children with chronic renal insufficiency children with idiopathic short stature children with short stature genetic disorders affecting growth pituitary dwarfism |
| gptkbp:usedIn |
treatment of growth hormone deficiency
sports doping HIV-infected patients with anemia dialysis patients preoperative patients to reduce transfusion |
| gptkbp:WADAStatus |
prohibited
|
| gptkbp:bfsParent |
gptkb:Ghrelin
gptkb:pituitary_gland gptkb:adrenal_gland gptkb:151096-09-2 gptkb:170729-80-3 gptkb:hormone |
| gptkbp:bfsLayer |
6
|